01302 LIFETECH SCI
- 1.710
- +0.030+1.79%
LIFETECH SCI News
先健科技：2023年度報告
Xianjian Advanced Technology Limited sold 21.72 million shares of Xianjian Technology (01302.HK) common shares worth approximately HK$38.01 million off the market
On April 16, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 16, Xianjian Advanced Technology Limited sold $21.72 million shares of $Xianjian Technology (01302.HK) over the market at an average price of HK$1.75 per share, worth approximately HK$38.01 million on April 15. After the sale, Xianjian Advanced Technology Limited's latest shareholding was 760 million shares, and the good position ratio dropped from 16.89% to 16.42%. book
Lifetech Scientific Buys Shares For Employee Incentive Scheme
Lifetech Scientific (HKG:1302) has agreed to acquire 21.7 million shares for its share award scheme, according to a Wednesday filing on the Hong Kong bourse. The company will purchase the shares from
Xianjian Technology (01302.HK): The trustee purchased 21.72 million shares in connection with the share award program
Gelonghui, April 10, 丨 Xianjian Technology (01302.HK) announced that on April 10, 2024, the trustee, seller and company entered into the agreement. According to this, for the share award plan, the trustee (with instructions from the company) agreed to buy (funded by the company) and the seller agreed to sell 21.72 million shares. The price of the shares to be sold was HK$1.750 per share to be sold. The purpose of adopting the share award scheme is to recognize, motivate and reward the contributions made by a number of eligible participants in order to maintain their continued effectiveness in the Group's operations and development.
Lifetech Scientific Unit Invests 340 Million Yuan in Structured Deposits
Lifetech Scientific (HKG:1302) unit Lifetech Shenzhen subscribed to 340 million yuan worth of structured deposits offered by Bank of Ningbo from Jan. 13, 2023, to March 28, a Tuesday filing on the Hon
Press Release: LifeTech Scientific Corporation Announced 2023 Annual Results: International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid Development
LifeTech Scientific Corporation Announced 2023 Annual Results: International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid Development PR Newswire SHENZHEN, China, Apr
Xianjian Technology (01302.HK) subscribes to a capital protected structured deposit
Gelonghui, April 2, 丨 Xianjian Technology (01302.HK) announced that Xianjian Shenzhen, a wholly-owned subsidiary of the company, and Bank of Ningbo have signed such structured deposit agreements between January 12, 2023 and March 28, 2024. According to this, Xianjian Shenzhen subscribes to capital protected floating income structured deposits issued by Bank of Ningbo, with a total principal amount of RMB 340 million.
Xianjian Technology (01302.HK): Increased R&D investment, looking forward to continuous gains in the innovation pipeline
Net profit after deducting non-return to mother in 2023 was slightly lower than what we expected the company to announce in 2023: revenue of 1.27 billion yuan, +15.5% year over year; net profit after deducting non-return to mother was 420 million yuan, -2.3% year over year. The income matches us
Xianjian Technology disclosed a “fake” financial report. The slight decline in performance was an indication. Overseas revenue increased by 30% and subsidiary valuations increased 1.7 times
① Xianjian Technology achieved revenue of 1,267 billion yuan in 2023, an increase of 15.5% year on year; net profit after deducting non-return to mother was 423 million yuan, a slight decrease of 2.3% year on year; ② The valuation of the subsidiary Yuanxin Technology after Series B financing increased sharply by 173%, and the fair value of its redeemable shares increased significantly accordingly.
Lifetech Scientific Books Lower 2023 Profit Despite Surge in Revenue
Lifetech Scientific (HKG:1302) posted a net profit attributable to owners of about 263.2 million yuan for the year ended Dec. 31, 2023, down from 325.3 million yuan in the previous year, according to
Xianjian Technology Announces 2023 Annual Results: Strong International Business Growth, Steady Development Driven by Innovation
SHENZHEN, March 28, 2024/PRNewswire/ -- On March 28, 2024, Xianjian Technology (“the Company” or “Xianjian Technology”, stock code: 1302.HK) and its subsidiaries (collectively, the “Group”) announced audited comprehensive results for the year ended December 31, 2023 (“during the reporting period”): Strong international business growth: The Group achieved sales revenue of approximately RMB 1,267.2 million, an increase of about 15.5% year on year, including overseas markets Sales increased significantly year over year by approximately 3
Xianjian Technology (01302) announced annual results. Profit attributable to shareholders of 263 million yuan decreased by 19.09% year-on-year
According to the Zhitong Finance App, Xianjian Technology (01302) announced the results for the year ended December 31, 2023. The group obtained revenue of RMB 1,267 billion (same unit), an increase of 15.48% over the previous year; profit attributable to the company owners was 263 million yuan, a decrease of 19.09% over the previous year; and the basic profit per share was 6 points. According to the announcement, the increase in revenue was mainly due to increased revenue from sales of congenital heart disease occulators and laminated stents.
LIFETECH SCI: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
LifeTech Scientific Flags Significant Profit Drop in 2023
LifeTech Scientific (HKG:1302) expects to record a "significant" decline in net profit for the year ended December 2023 when compared to 2022, according to a Friday filing with the Hong Kong bourse. T
Xianjian Technology (01302) issued a profit warning. Annual net profit is expected to drop significantly year-on-year
Xianjian Technology (01302) announced that the Group's net profit for the year ended December 31, 2023 is expected to be 2...
先健科技：盈利預警
LIFETECH SCI: NOTICE OF BOARD MEETING
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Southwest Securities: There is still a lot of room for penetration in the coronary artery disease interventional treatment market, focus on Sano Healthcare (688108.SH), etc.
Coronary heart disease is the leading cause of death in the world, and there is still plenty of room for penetration in the interventional treatment market for coronary artery disease in China.
Germany to Approve Cannabis Bill This Week in Legalization Drive
German lawmakers will approve delayed legislation decriminalizing personal use of cannabis this week, paving the way for it to take effect on April 1, according to Health Minister Karl Lauterbach.
Analysis
Price Target
No Data
